Evidence map›Paper›PMID 29305435›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.

Payal Mittal, Rebecca Abblett, Joseph M Ryan, Adam T Hagymasi, Archibald Agyekum-Yamoah, Julia Svedova, Steven L Reiner, Marie-Clare St Rose, Matthew P Hanley, Anthony T Vella and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  2. Review
  3. Article
  4. VEGF-A enhances the cytotoxic function of CD4Journal of translational medicine · 2023
    Article
  5. Review
  6. Review
  7. Cytotoxic CD4eLife · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Payal MittalDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.
Rebecca AbblettDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.ORCID 0000-0002-1175-7020
Joseph M RyanDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.ORCID 0000-0002-6333-9533
Adam T HagymasiDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.
Archibald Agyekum-YamoahDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.
Julia SvedovaDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.ORCID 0000-0003-0836-4725
Steven L ReinerDepartment of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University, New York, NY 10032; and.ORCID 0000-0002-1635-8619
Marie-Clare St RoseDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.
Matthew P HanleyDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.ORCID 0000-0003-1560-9997
Anthony T VellaDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.
Adam J AdlerDepartment of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030; aadler@uchc.edu.ORCID 0000-0002-7970-155X
University of Connecticut · USColumbia University · US

Funding

Asymmetric Lymphocyte Division in the Immune ResponseR01AI076458 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI REINER, STEVEN L · 2008 to 2019
$3.7M
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced CostimulationR01CA109339 · NCI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ADLER, ADAM J, VELLA, ANTHONY T · 2004 to 2015
$2.9M
Diversifying and Regenerating T Cell FunctionR01AI113365 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REINER, STEVEN L · 2014 to 2018
$2.0M
Breaking Tolerance to Induce Tumor-Specific Cytotoxic CD4 Th1 CellsR01AI094640 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI ADLER, ADAM J, VELLA, ANTHONY T · 2012 to 2016
$1.9M
NCI NIH HHS R01 CA109339NIAID NIH HHS R01 AI076458NIAID NIH HHS R01 AI094640NIAID NIH HHS R01 AI113365
6 · The paper itself

Abstract

Agonists to the TNF/TNFR costimulatory receptors CD134 (OX40) and CD137 (4-1BB) elicit antitumor immunity. Dual costimulation with anti-CD134 plus anti-CD137 is particularly potent because it programs cytotoxic potential in CD8

Indexed as

AnimalsCD4-Positive T-LymphocytesCell DifferentiationCore Binding Factor Alpha 3 SubunitImmunotherapyLymphocyte ActivationMelanoma, ExperimentalMiceMice, TransgenicReceptors, OX40T-Box Domain ProteinsTranscription FactorsTumor Necrosis Factor Receptor Superfamily, Member 9Core Binding Factor Alpha 3 SubunitEomes protein, mouseReceptors, OX40Runx3 protein, mouseT-Box Domain ProteinsTnfrsf4 protein, mouseTranscription FactorsTumor Necrosis Factor Receptor Superfamily, Member 9Zbtb7b protein, mouse

Identifiers

PMID29305435
PMCPMC5809300
OpenAlexW2782274536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.